fda warning letter glp-1 october 2025 Democratic lawmakers are pressing the Trump administration to disclose who received special access to Eli Lilly's investigational obesity drug retatrutide. Sen. Maggie Hassan (D-N.H.) sent a to HHS Secretary Robert F One Year Later, FDA Reorg

Lower metabolic rate from weight loss, hormonal changes

Trends in insulin resistance: Insights into mechanisms and therapeutic strategy

Abstract Osteoarthritis (OA) is a common disabling disease worldwide, with no effective and safe disease-modifying drugs (DMOAD) in the market

Moreover, as these mechanisms of action may occur concurrently, it is important to investigate alterations in drug exposure when multiple mechanisms are considered simultaneously

There is a high likelihood of regaining weight

Additionally, in the CARDIOCHUS-CHOP registry, patients with recovered LVEF had significantly lower mortality and hospitalization rates compared to both HFrEF (mortality RR 0.71 [0.540.92], hospitalization RR 0.89 [0.751.0]) and HFpEF patients (mortality RR 0.70 [0.540.89], hospitalization RR 0.86 [0.761.0]) 12